Xsolla Web Shop and Singular Join Forces to Deliver Cross-Platform LTV and ROAS Measurement Solutions
10.9.2025 15:00:00 CEST | Business Wire | Press release
Xsolla Web Shop and Singular S2S Integration Bridges the Gap Between Mobile Marketing and Web Transactions for Complete Campaign Visibility
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a new mobile-focused Server-to-Server (S2S) integration with Singular, a leading marketing analytics and attribution platform. The integration unifies mobile marketing data with direct-to-consumer web purchases, enabling developers to measure campaign performance and player value more accurately than ever before.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910813948/en/
Graphic: Xsolla
As mobile game makers increasingly turn to Web Shops to expand revenue streams beyond app stores, one challenge has persisted: how to tie those off-platform transactions back to mobile marketing spend. The Xsolla Web Shop + Singular S2S integration closes this gap by treating Web Shop purchases as attributable events, giving developers true Return on Advertising Spend (ROAS) and comprehensive Lifetime Value (LTV) insights.
Key advantages of the Xsolla Web Shop + Singular S2S integration:
- Capture both mobile and web purchases as part of a single funnel
- Link revenue directly to user acquisition and re-engagement campaigns
- Reveal the complete LTV picture across app and Web Shop transactions
With this integration, Web Shop purchases are transmitted to Singular as server-to-server events, then mapped back to the correct install source or re-engagement campaign. This provides growth teams with a single, trusted view of performance across all platforms.
“Having launched more than 600 mobile Web Shops, we’ve seen developers demand actionable data that connects web monetization with mobile marketing,” said Berkley Egenes, Chief Marketing & Growth Officer at Xsolla. “Our new S2S integration with Singular delivers that missing link, giving teams the clarity to optimize and scale their Web Shop strategies confidently.”
“Our goal at Singular has always been to simplify complex data and make it actionable for growth teams,” said Gadi Eliashiv, CEO and Co-Founder at Singular. “By partnering with Xsolla, we’re giving developers the full-funnel visibility they need to measure ROI and maximize revenue across every platform.”
Learn more about the S2S integration for Xsolla Web Shop and Singular at: https://xsolla.pro/singular
About Xsolla
Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.
For more information, visit xsolla.com
About Singular
Singular is the only end-to-end marketing attribution and analytics platform that uncovers true ROI across all marketing channels. We transform complex marketing data into actionable insights by unifying campaign data from thousands of channels with cross-device attribution data. Leading brands like LinkedIn, Nike, WB Games, and Rovio rely on Singular to maximize every marketing dollar, eliminate wasted spend, and drive higher user retention. With superior ROI reporting, advanced fraud prevention, user engagement capabilities, and unmatched data accessibility, marketers can finally drive faster growth with smarter insights.
Learn more at singular.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20250910813948/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom